Bridgefront Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bridgefront Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,724	Closed	-$370K	–	601
2025 Q2	$370K	Buy	+6,724	New	+$396K	0.1%	355
2024 Q4	–	Sell	-8,235	Closed	-$579K	–	592
2024 Q3	$579K	Buy	+8,235	New	+$688K	0.22%	146
2022 Q2	–	Sell	-4,407	Closed	-$340K	–	309
2022 Q1	$340K	Buy	+4,407	New	+$369K	0.42%	75
2021 Q4	–	Sell	-5,623	Closed	-$435K	–	310
2021 Q3	$435K	Buy	5,623 +3,031	+117%	+$239K	0.45%	56
2021 Q2	$216K	Buy	+2,592	New	+$205K	0.08%	481

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bridgefront Capital's BMRN Position: Q3 2025 in Review

Bridgefront Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 6,724 shares — an estimated $370K sold.

Bridgefront Capital first reported a position in BMRN in Q2 2021 and held it in 5 quarters. The position peaked at $579K in Q3 2024. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

Bridgefront Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Bridgefront Capital sold 6,724 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $370K.
Bridgefront Capital first reported a position in BioMarin Pharmaceuticals in Q2 2021 and held it in 5 quarters.
Bridgefront Capital's BioMarin Pharmaceuticals position peaked at $579K in Q3 2024.
576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Bridgefront Capital's 13F filing for Q3 2025, filed 14 Nov 2025.